Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
March 21, 2017 07:00 ET
|
Heat Biologics
ELISPOT results suggest that HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients Tumor reduction corresponds to enhanced immune...
Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
March 16, 2017 07:02 ET
|
Heat Biologics
Grant to fund Dr. Natasa Strbo’s Zika preclinical research at the University of Miami DURHAM, N.C., March 16, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...
Heat Biologics Meets Efficacy Endpoint in its Phase 1b Lung Cancer Trial to Progress to Phase 2
March 13, 2017 07:00 ET
|
Heat Biologics
Encouraging results evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®) Signs of synergistic efficacy with nivolumab enables expansion to...
Heat Biologics to Present at 29th Annual ROTH Conference
March 09, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 09, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Announces Agreement to Acquire Pelican Therapeutics
March 08, 2017 07:00 ET
|
Heat Biologics
Acquisition brings $15.2 million CPRIT grant to fund 70-patient Phase I trial DURHAM, N.C., March 08, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...
Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting
March 02, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Presents Immune Data on its HS-410 Phase 2 Bladder Cancer Trial at the Genitourinary Cancers Symposium
February 17, 2017 07:00 ET
|
Heat Biologics
DURHAM, N.C., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), announced that it presented a poster of its immunological data from its 94-patient Phase 2 trial...
Heat Biologics to Present at the Genitourinary Cancers Symposium
February 14, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at NobleCon13
January 24, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics to Present at Biotech Showcase 2017 Conference in San Francisco
January 05, 2017 08:00 ET
|
Heat Biologics
DURHAM, N.C., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...